1
|
Ahmadinejad N, Azizinik F, Khosravi P, Torabi A, Mohajeri A, Arian A. Evaluation of Features in Probably Benign and Malignant Nonmass Enhancement in Breast MRI. Int J Breast Cancer 2024; 2024:6661849. [PMID: 38523651 PMCID: PMC10959584 DOI: 10.1155/2024/6661849] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/08/2023] [Revised: 12/08/2023] [Accepted: 02/27/2024] [Indexed: 03/26/2024] Open
Abstract
Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) is a highly sensitive breast imaging modality in detecting breast carcinoma. Nonmass enhancement (NME) is uniquely seen on MRI of the breast. The correlation between NME features and pathologic results has not been extensively explored. Our goal was to evaluate the characteristics of probably benign and suspicious NME lesions in MRI and determine which features are more associated with malignancy. We performed a retrospective research after approval by the hospital ethics committee on women who underwent breast MRI from March 2017 to March 2020 and identified 63 lesions of all 400 NME that were categorized as probably benign or suspicious according to the BI-RADS classification (version 2013). MRI features of NME findings including the location, size, distribution and enhancement pattern, kinetic curve, diffusion restriction, and also pathology result or 6-12-month follow-up MRI were evaluated and analyzed in each group (probably benign or suspicious NME). Vacuum-guided biopsies (VAB) were performed under mammographic or sonographic guidance and confirmed with MRI by visualization of the inserted clips. Segmental distribution and clustered ring internal enhancement were significantly associated with malignancy (p value<0.05), while linear distribution or homogeneous enhancement patterns were associated with benignity (p value <0.05). Additionally, the plateau and washout types in the dynamic curve were only seen in malignant lesions (p value <0.05). The presence of DWI restriction in NME lesions was also found to be a statistically important factor. Understanding the imaging findings of malignant NME is helpful to determine when biopsy is indicated. The correlation between NME features and pathologic results is critical in making appropriate management.
Collapse
Affiliation(s)
- Nasrin Ahmadinejad
- Advanced Diagnostic and Interventional Radiology Research Center (ADIR), Imam Khomeini Hospital, Cancer Institute, Tehran University of Medical Sciences, Tehran, Iran
| | - Fahimeh Azizinik
- Advanced Diagnostic and Interventional Radiology Research Center (ADIR), Imam Khomeini and Yas Hospital, Cancer Institute, Tehran University of Medical Sciences, Tehran, Iran
| | - Pershang Khosravi
- Department of Radiology, Imam Khomeini Hospital, Tehran University of Medical Sciences, Tehran, Iran
| | - Ala Torabi
- Department of Radiology, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran
| | | | - Arvin Arian
- Advanced Diagnostic and Interventional Radiology Research Center (ADIR), Imam Khomeini Hospital, Cancer Institute, Tehran University of Medical Sciences, Tehran, Iran
| |
Collapse
|
2
|
Hao Y, Luo J, Wang Y, Li Z, Wang X, Yan F. Ultrasound molecular imaging of p32 protein translocation for evaluation of tumor metastasis. Biomaterials 2023; 293:121974. [PMID: 36566551 DOI: 10.1016/j.biomaterials.2022.121974] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/06/2022] [Revised: 12/02/2022] [Accepted: 12/17/2022] [Indexed: 12/23/2022]
Abstract
Protein translocation is an essential process for living cells to respond to different physiological, pathological or environmental stimuli. However, its abnormal occurrence usually results in undesirable outcomes such as tumors. To date, there is still a lack of appropriate methods to detect this event in live animals in a real-time manner. Here, we identified the gradually increased cell-surface translocation of p32 protein from mitochondria during tumor progression. LyP-1-modified gas vesicles (LyP-1-GVs) were developed through conjugating LyP-1 (p32-targeting peptide) to the biosynthetic GVs to monitor the cell-surface level of p32 translocation. The resulting LyP-1-GVs have about 200 nm particle size and good tumor cell targeting performance. Upon systemic administration, LyP-1-GVs can traverse through blood vessels and bind to the tumor cells, producing strong contrast imaging signals in comparison with the non-targeted GVs. The contrast imaging signals correlate well with the cell-surface translocation level of p32 protein and tumor metastatic ability. To our knowledge, this is the first report about the in vivo detection of protein translocation to cell membrane from mitochondria by ultrasound molecular imaging. Our study provides a new strategy to explore the molecular events of protein membrane translocations for evaluation of tumor metastasis at the live animal level.
Collapse
Affiliation(s)
- Yongsheng Hao
- Center for Cell and Gene Circuit Design, CAS Key Laboratory of Quantitative Engineering Biology, Shenzhen Institute of Synthetic Biology, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen 518055, PR China; Shenzhen College of Advanced Technology, University of the Chinese Academy of Sciences, Beijing 100049, PR China
| | - Jingna Luo
- Department of Ultrasound, The Second People's Hospital of Shenzhen, The First Affiliated Hospital of Shenzhen University, Shenzhen 518061, PR China; Shenzhen University Health Science Center, Shenzhen 518000, PR China
| | - Yuanyuan Wang
- Center for Cell and Gene Circuit Design, CAS Key Laboratory of Quantitative Engineering Biology, Shenzhen Institute of Synthetic Biology, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen 518055, PR China
| | - Zhenzhou Li
- Department of Ultrasound, The Second People's Hospital of Shenzhen, The First Affiliated Hospital of Shenzhen University, Shenzhen 518061, PR China; Shenzhen University Health Science Center, Shenzhen 518000, PR China
| | - Xiangwei Wang
- Department of Urology & Carson International Cancer Center, Shenzhen University General Hospital & Shenzhen University Clinical Medical Academy Center, Shenzhen University, Shenzhen 518055, PR China
| | - Fei Yan
- Center for Cell and Gene Circuit Design, CAS Key Laboratory of Quantitative Engineering Biology, Shenzhen Institute of Synthetic Biology, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen 518055, PR China.
| |
Collapse
|
3
|
Wang J, Wang Y, Jia J, Liu C, Ni D, Sun L, Guo Z. Dual-Modality Molecular Imaging of Tumor via Quantum Dots-Liposome-Microbubble Complexes. Pharmaceutics 2022; 14:pharmaceutics14112510. [PMID: 36432701 PMCID: PMC9699378 DOI: 10.3390/pharmaceutics14112510] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/08/2022] [Revised: 11/07/2022] [Accepted: 11/15/2022] [Indexed: 11/22/2022] Open
Abstract
Molecular imaging has demonstrated promise for evaluating the expression levels of biomarkers for the early prediction of tumor progression and metastasis. However, most of the commonly used molecular imaging modalities are relatively single and have difficulties imaging complex biological processes. Here, we fabricated αvβ3-integrin-targeted quantum-dots-loaded liposome-microbubble (iRGD-QDLM) complexes that combined ultrasound imaging with optical imaging. The resulting iRGD-QDLM has excellent binding capability to 4T1 breast cancer cells. Ultrasound molecular imaging of 4T1 tumors demonstrated that significantly enhanced ultrasound molecular signals could be observed in comparison with non-targeted QDLM. Importantly, our study also suggested that iRGD-QDL on the surface of microbubbles could be delivered into a tumor by ultrasound-mediated microbubble destruction and adhered to αvβ3 integrin on breast cancer cells, achieving transvascular fluorescent imaging. Our study provides a novel approach to dual-modality molecular imaging of αvβ3 integrin in the tumor tissue.
Collapse
Affiliation(s)
- Jieqiong Wang
- Department of Rehabilitation Medicine, Huashan Hospital, Fudan University, Shanghai 201206, China
| | - Yuanyuan Wang
- Center for Cell and Gene Circuit Design, Shenzhen Institute of Synthetic Biology, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen 518055, China
| | - Jie Jia
- Department of Rehabilitation Medicine, Huashan Hospital, Fudan University, Shanghai 201206, China
| | - Chenxing Liu
- Center for Cell and Gene Circuit Design, Shenzhen Institute of Synthetic Biology, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen 518055, China
| | - Dong Ni
- Medical Ultrasound Image Computing (MUSIC) Laboratory, Shenzhen University, Shenzhen 518055, China
| | - Litao Sun
- Department of Ultrasound Medicine, Zhejiang Provincial People’s Hospital (Hangzhou Medical College Affiliated People’s Hospital), Hangzhou 310014, China
- Correspondence: (L.S.); (Z.G.); Tel.: +86-755-2962-9333 (Z.G.)
| | - Zhijie Guo
- Department of Ultrasound, Shenzhen Bao’an Chinese Medicine Hospital, Guangzhou University of Chinese Medicine, Shenzhen 518133, China
- Correspondence: (L.S.); (Z.G.); Tel.: +86-755-2962-9333 (Z.G.)
| |
Collapse
|
4
|
Liu G, Li Y, Chen SL, Chen Q. Non-mass enhancement breast lesions: MRI findings and associations with malignancy. ANNALS OF TRANSLATIONAL MEDICINE 2022; 10:357. [PMID: 35433999 PMCID: PMC9011203 DOI: 10.21037/atm-22-503] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 12/22/2021] [Accepted: 03/18/2022] [Indexed: 12/02/2022]
Abstract
Background Magnetic resonance imaging (MRI) is a multi-sequence imaging technique. Although MRI is the most sensitive method for detecting breast cancer, it is limited in evaluating the malignant possibility of non-mass enhanced (NME) breast lesions. It is also rarely reported whether MRI can further indicate the invasion of the lesions. In this article, we explore the differentiation of MRI characteristics between benign and malignant NME lesions and determine which features are associated with invasion. Methods The MRI findings of 118 NME lesions were evaluated retrospectively to explore the characteristics of the benign and malignant NME lesions in different MRI sequences including dynamic contrast-enhanced (DCE) MRI and diffusion-weighted imaging (DWI). The difference of MRI findings between benign and malignant NME lesions were determined by Pearson χ2 test or Fisher's exact test, and the diagnostic value of features for malignancy was evaluated by receiver operating characteristic (ROC) curve. Results This study included 118 NME lesions (62 benign and 56 malignant) in 118 patients. We found a segmental distribution, clustered-ring enhancement, wash-out dynamic curve, and lower apparent diffusion coefficient (ADC) value (P=0.01, <0.001, 0.02, 0.001) were associated with malignancy. Wash-out dynamic curves, diffusion restriction on DWI, lower ADC values were more advantageous in distinguishing invasive NME cancer from benign lesions than ductal carcinoma in situ (DCIS) (P<0.001, <0.001, 0.027). Further analysis showed that there were statistical differences between invasive carcinoma and carcinoma in situ in terms of wash-out dynamic curves, diffusion restriction on DWI and lower ADC values (P=0.001, 0.014, 0.024). Conclusions MRI is a valuable way to identify malignant NME lesions and could predict the invasion of the lesions. Compared with carcinoma in situ, some sequences have more advantages in distinguishing invasive carcinoma from benign lesions.
Collapse
Affiliation(s)
- Gang Liu
- Department of Radiology, The First Medical Center of Chinese PLA General Hospital, Beijing, China
| | - Ying Li
- Department of Radiology, The First Medical Center of Chinese PLA General Hospital, Beijing, China
| | - Si-Lu Chen
- Department of Radiology, The First Medical Center of Chinese PLA General Hospital, Beijing, China
- Department of Radiology, The Seventh Medical Center of Chinese PLA General Hospital, Beijing, China
| | - Qiao Chen
- Department of Radiology, The First Medical Center of Chinese PLA General Hospital, Beijing, China
| |
Collapse
|
5
|
Avendano D, Marino MA, Leithner D, Thakur S, Bernard-Davila B, Martinez DF, Helbich TH, Morris EA, Jochelson MS, Baltzer PAT, Clauser P, Kapetas P, Pinker K. Limited role of DWI with apparent diffusion coefficient mapping in breast lesions presenting as non-mass enhancement on dynamic contrast-enhanced MRI. Breast Cancer Res 2019; 21:136. [PMID: 31801635 PMCID: PMC6894318 DOI: 10.1186/s13058-019-1208-y] [Citation(s) in RCA: 39] [Impact Index Per Article: 7.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/10/2019] [Accepted: 10/03/2019] [Indexed: 02/07/2023] Open
Abstract
BACKGROUND Available data proving the value of DWI for breast cancer diagnosis is mainly for enhancing masses; DWI may be less sensitive and specific in non-mass enhancement (NME) lesions. The objective of this study was to assess the diagnostic accuracy of DWI using different ROI measurement approaches and ADC metrics in breast lesions presenting as NME lesions on dynamic contrast-enhanced (DCE) MRI. METHODS In this retrospective study, 95 patients who underwent multiparametric MRI with DCE and DWI from September 2007 to July 2013 and who were diagnosed with a suspicious NME (BI-RADS 4/5) were included. Twenty-nine patients were excluded for lesion non-visibility on DWI (n = 24: 12 benign and 12 malignant) and poor DWI quality (n = 5: 1 benign and 4 malignant). Two readers independently assessed DWI and DCE-MRI findings in two separate randomized readings using different ADC metrics and ROI approaches. NME lesions were classified as either benign (> 1.3 × 10-3 mm2/s) or malignant (≤ 1.3 × 10-3 mm2/s). Histopathology was the standard of reference. ROC curves were plotted, and AUCs were determined. Concordance correlation coefficient (CCC) was measured. RESULTS There were 39 malignant (59%) and 27 benign (41%) lesions in 66 (65 women, 1 man) patients (mean age, 51.8 years). The mean ADC value of the darkest part of the tumor (Dptu) achieved the highest diagnostic accuracy, with AUCs of up to 0.71. Inter-reader agreement was highest with Dptu ADC max (CCC 0.42) and lowest with the point tumor (Ptu) ADC min (CCC = - 0.01). Intra-reader agreement was highest with Wtu ADC mean (CCC = 0.44 for reader 1, 0.41 for reader 2), but this was not associated with the highest diagnostic accuracy. CONCLUSIONS Diagnostic accuracy of DWI with ADC mapping is limited in NME lesions. Thirty-one percent of lesions presenting as NME on DCE-MRI could not be evaluated with DWI, and therefore, DCE-MRI remains indispensable. Best results were achieved using Dptu 2D ROI measurement and ADC mean.
Collapse
Affiliation(s)
- Daly Avendano
- Department of Radiology, Breast Imaging Service, Memorial Sloan Kettering Cancer Center, Suite 705, 300 E 66th Street, New York, NY, 10065, USA.,Department of Breast Imaging, Breast Cancer Center TecSalud, ITESM Monterrey, Monterrey, Nuevo Leon, Mexico
| | - Maria Adele Marino
- Department of Radiology, Breast Imaging Service, Memorial Sloan Kettering Cancer Center, Suite 705, 300 E 66th Street, New York, NY, 10065, USA.,Department of Biomedical Sciences and Morphologic and Functional Imaging, University of Messina, Messina, Italy
| | - Doris Leithner
- Department of Radiology, Breast Imaging Service, Memorial Sloan Kettering Cancer Center, Suite 705, 300 E 66th Street, New York, NY, 10065, USA.,Department of Diagnostic and Interventional Radiology, University Hospital Frankfurt, Frankfurt, Germany
| | - Sunitha Thakur
- Department of Medical Physics, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY, 10065, USA
| | - Blanca Bernard-Davila
- Department of Radiology, Breast Imaging Service, Memorial Sloan Kettering Cancer Center, Suite 705, 300 E 66th Street, New York, NY, 10065, USA
| | - Danny F Martinez
- Department of Radiology, Breast Imaging Service, Memorial Sloan Kettering Cancer Center, Suite 705, 300 E 66th Street, New York, NY, 10065, USA
| | - Thomas H Helbich
- Division of Molecular and Gender Imaging, Department of Biomedical Imaging and Image-Guided Therapy, Medical University of Vienna, Vienna, Austria
| | - Elizabeth A Morris
- Department of Radiology, Breast Imaging Service, Memorial Sloan Kettering Cancer Center, Suite 705, 300 E 66th Street, New York, NY, 10065, USA
| | - Maxine S Jochelson
- Department of Radiology, Breast Imaging Service, Memorial Sloan Kettering Cancer Center, Suite 705, 300 E 66th Street, New York, NY, 10065, USA
| | - Pascal A T Baltzer
- Division of Molecular and Gender Imaging, Department of Biomedical Imaging and Image-Guided Therapy, Medical University of Vienna, Vienna, Austria
| | - Paola Clauser
- Division of Molecular and Gender Imaging, Department of Biomedical Imaging and Image-Guided Therapy, Medical University of Vienna, Vienna, Austria
| | - Panagiotis Kapetas
- Division of Molecular and Gender Imaging, Department of Biomedical Imaging and Image-Guided Therapy, Medical University of Vienna, Vienna, Austria
| | - Katja Pinker
- Department of Radiology, Breast Imaging Service, Memorial Sloan Kettering Cancer Center, Suite 705, 300 E 66th Street, New York, NY, 10065, USA. .,Division of Molecular and Gender Imaging, Department of Biomedical Imaging and Image-Guided Therapy, Medical University of Vienna, Vienna, Austria.
| |
Collapse
|
6
|
Marino MA, Avendano D, Zapata P, Riedl CC, Pinker K. Lymph Node Imaging in Patients with Primary Breast Cancer: Concurrent Diagnostic Tools. Oncologist 2019; 25:e231-e242. [PMID: 32043792 PMCID: PMC7011661 DOI: 10.1634/theoncologist.2019-0427] [Citation(s) in RCA: 98] [Impact Index Per Article: 19.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/03/2019] [Accepted: 08/12/2019] [Indexed: 12/26/2022] Open
Abstract
The detection of lymph node metastasis affects the management of patients with primary breast cancer significantly in terms of staging, treatment, and prognosis. The main goal for the radiologist is to determine and detect the presence of metastatic disease in nonpalpable axillary lymph nodes with a positive predictive value that is high enough to initially select patients for upfront axillary lymph node dissection. Features that are suggestive of axillary adenopathy may be seen with different imaging modalities, but ultrasound is the method of choice for evaluating axillary lymph nodes and for performing image-guided lymph node interventions. This review aims to provide a comprehensive overview of the available imaging modalities for lymph node assessment in patients diagnosed with primary breast cancer. IMPLICATIONS FOR PRACTICE: The detection of lymph node metastasis affects the management of patients with primary breast cancer. The main goal for the radiologist is to detect lymph node metastasis in patients to allow for the selection of patients who should undergo upfront axillary lymph node dissection. Features that are suggestive of axillary adenopathy may be seen with mammography, computed tomography, and magnetic resonance imaging, but ultrasonography is the imaging modality of choice for evaluating axillary lymph nodes. A normal axillary lymph node is characterized by a reniform shape, a maximal cortical thickness of 3 mm without focal bulging, smooth margins, and, depending on size, a discernable central fatty hilum.
Collapse
Affiliation(s)
- Maria Adele Marino
- Department of Biomedical Sciences and Morphologic and Functional Imaging, Policlinico Universitario G. Martino, University of MessinaMessinaItaly
| | - Daly Avendano
- Department of Breast Imaging, Breast Cancer Center TecSalud, Instituto Tecnológico de Estudios Superiores (ITESM) MonterreyNuevo LeonMexico
| | - Pedro Zapata
- Department of Radiology, San Felipe de Jesus HospitalMonterreyNuevo LeonMexico
| | - Christopher C. Riedl
- Breast Imaging Service, Department of Radiology, Memorial Sloan Kettering Cancer CenterNew YorkNew YorkUSA
| | - Katja Pinker
- Breast Imaging Service, Department of Radiology, Memorial Sloan Kettering Cancer CenterNew YorkNew YorkUSA
- Molecular and Gender Imaging Service, Department of Biomedical Imaging and Image‐guided Therapy, Medical University of ViennaViennaAustria
| |
Collapse
|